{"id":"396","presentation":"BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH","session":"AS01 - Allergy and Airway","filename":"mehtaan-209584-0001-CHEST_ePoster_V2.00-FINAL.pptx","speaker":"Eduardo Urdaneta","photo":"","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-presentations\/wchest20\/396\/jpg\/mehtaan-209584-0001-chest_eposter_v2.00-final\/thumbnails\/0.png","html5":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-presentations\/wchest20\/396\/html\/mehtaan-209584-0001-chest_eposter_v2.00-final\/data\/","what":"html5","code":"","priority":["html5","pdf","jpg","thumbnail"]}
[speaker]
[presentation]
[session]